Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749324 | 0.82 | BRPF1 (0.46) | BRPF1CHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL6750933 | 0.81 | SMYD3 (0.44) | BRPF1CHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL2451058 | 0.79 | TP53 (0.47) | KDM4EMEN1KMT2AALOX15HSD17B10 | |
| SCHEMBL6747189 | 0.77 | MEN1 (0.45) | CCR2MEN1KMT2AHPGDCYP1A2 | |
| SCHEMBL5436506 | 0.75 | NR1H2 (0.44) | BRPF1CHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL5107559 | 0.75 | P2RX4 (0.41) | BRPF1CHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL6479624 | 0.75 | BRPF1 (0.43) | BRPF1CHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL5101602 | 0.73 | PRKCI (0.50) | BRPF1CHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL6229626 | 0.73 | AKR1C3 (0.50) | BRPF1CHEK1AURKADAPK3CSNK1A1 | |
| SCHEMBL6253573 | 0.73 | BRPF1 (0.41) | BRPF1CHEK1AURKADAPK3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137395-A1 | Novel quinoline derivatives | AGOURON PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | disclosed |
| US-6833456-B2 | Heterocyclic sulfides such as 5-(2-(2R-Hydroxymethyl-pyrrolidine-1-carbonyl)-thieno(3,2-b)pyridin-7 -ylamino)-2-methyl-indole-1-carboxylic acid methylamide, used as angiogenesis inhibitors | AGOURON PHARMACEUTICALS, INC. | 2004-12-21 | — | — | US | disclosed |
| EP-1483268-A2 | INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | ROMINES WILLIAM HENRY (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2003074529-A2 | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | COQ8B, COQ8A, MCM5 | BRPF1 2910/4885CHEK1 239/4885AURKA 2459/4885 |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | CDKN1A, CCNA1, TYMP | BRPF1 1746/4885CHEK1 195/4885AURKA 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.